naa a22 4500 510763251 CHVBK 20180411083147.0 cr unu---uuuuu 180411e20130601xx s 000 0 eng 10.1007/s12094-012-0985-x doi (NATIONALLICENCE)springer-10.1007/s12094-012-0985-x Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor [Elektronische Daten] [F. Afonso, U. Anido, O. Fernández-Calvo, S. Vázquez-Estévez, L. León, M. Lázaro, M. Ramos, L. Antón-Aparicio] We performed a literature search that shed light on the signaling pathways involved in the sorafenib activity as first- or subsequent-line treatment, taking into account its toxicity profile. Sorafenib appears to have better tolerability when compared with other agents in the same indication. Cross-resistance between tyrosine kinase inhibitors (TKIs) may be limited, even after failure with a previous VEGFR inhibitor, but the optimal sequence with TKIs remains to be determined. Randomized trials of second-line treatment options have showed either modest or no differences in terms of progression-free and overall survival (OS). Direct comparison between sorafenib and axitinib demonstrated differences in terms of PFS in favor of axitinib, but not in terms of OS as second-line treatment. In contrast, a phase III study showed a benefit in OS, favoring sorafenib when compared with temsirolimus. In conclusion, after using other VEGF inhibitor such as sunitinib, sorafenib is active and safe for the treatment of patients with advanced or metastatic RCC. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Sorafenib nationallicence Renal cell carcinoma nationallicence Tyrosine kinase inhibitor nationallicence Second-line treatment nationallicence Afonso F. Complexo Hospitalario Arquitecto Marcide, Ferrol, Spain aut Anido U. Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain aut Fernández-Calvo O. Complexo Hospitalario Universitario de Ourense, Ourense, Spain aut Vázquez-Estévez S. Hospital Universitario Lucus Augustí, Lugo, Spain aut León L. Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain aut Lázaro M. Complexo Hospitalario Universitario, Vigo, Spain aut Ramos M. Centro Oncológico de Galica, A Coruña, Spain aut Antón-Aparicio L. Medical Oncology Service, Complexo Hospitalario Universitario A Coruña, 84 As Xubias, 15006, A Coruña, Spain aut Clinical and Translational Oncology Springer Milan 15/6(2013-06-01), 425-433 1699-048X 15:6<425 2013 15 12094 https://doi.org/10.1007/s12094-012-0985-x text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0985-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Afonso F. Complexo Hospitalario Arquitecto Marcide, Ferrol, Spain aut NATIONALLICENCE 700 1- Anido U. Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain aut NATIONALLICENCE 700 1- Fernández-Calvo O. Complexo Hospitalario Universitario de Ourense, Ourense, Spain aut NATIONALLICENCE 700 1- Vázquez-Estévez S. Hospital Universitario Lucus Augustí, Lugo, Spain aut NATIONALLICENCE 700 1- León L. Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain aut NATIONALLICENCE 700 1- Lázaro M. Complexo Hospitalario Universitario, Vigo, Spain aut NATIONALLICENCE 700 1- Ramos M. Centro Oncológico de Galica, A Coruña, Spain aut NATIONALLICENCE 700 1- Antón-Aparicio L. Medical Oncology Service, Complexo Hospitalario Universitario A Coruña, 84 As Xubias, 15006, A Coruña, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/6(2013-06-01), 425-433 1699-048X 15:6<425 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer